Skip to main content Back to Top

Caring for Patients with Opioid Use Disorder During COVID-19

Broadcast Date: August 10, 2020

 

Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Patients with opioid use disorder (OUD) require close monitoring and consistent access to care. This podcast focuses on providing care to this patient population during the COVID-19 pandemic. For more information on the pharmacist’s role in the management of OUD during the COVID-19 pandemic, as well as resources from the National Academy of Medicine Action Collaborative on Countering the US Opioid Epidemic, please see the full webinar recording at ASHP elearning.org.

HOST

Vicki BasalygaVicki Basalyga, Pharm.D., BCPS, BCPPS, is the Director for the Section of Clinical Specialists and Scientists. In this role Vicki serves as an information resource and provides guidance to ASHP members regarding science and scientific developments affecting pharmacy practice in health systems. She serves as secretary to the Section executive committee and coordinates activities to accomplish the objectives established by the Section. Additionally, Vicki has assumed the position of Council Secretary for the ASHP's Council on Therapeutics.

Vicki received her Doctor of Pharmacy from Duquesne University and completed an ASHP accredited PGY1 at Children’s National Medical Center in Washington, DC. Vicki is also a Board Certified Pharmacotherapy Specialist and a Board Certified Pediatric Pharmacotherapy Specialist.

Prior to her current position at ASHP, Vicki practiced as critical care pharmacist in both the Cardiac Intensive Care Unit and the Pediatric Intensive Care Unit at Children’s National Medical Center in Washington, DC. Other activities Vicki performed included drafting policies and procedures, co-chairing the Antimicrobial Stewardship Program, creating and drafting order sets for CPOE conversion and precepting residents and students.



The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.